Review





Similar Products

mouse monoclonal anti cav1 antibody  (Proteintech)
95
Proteintech mouse monoclonal anti cav1 antibody
A) Overview of treatment and phosphoproteome enrichment workflow. B) Phosphopeptides identified, quantified, and significant for each treatment and their interaction after correcting for matched unmodified peptides using MSStatsPTM in R. C) Volcano plots of phosphopeptide Log2FC of IFNγ treatment, LGALS1 siRNA, and both IFNγ and LGALS1 siRNA, compared to non-targeting control and vehicle plotted against –log10(p-value). Orange colour represents non-significant proteins, while blue colour represents those with p<0.01 (linear mixed-effects model), and green represents those with FDR: BH<0.2. D) Heatmap of 28 phosphopeptides significant in at least 1 comparison from panel C. Red colour indicates increased expression, blue colour indicates decreased expression, and black colour indicates phosphopeptides that were not found in that comparison. Colour on the top bar denotes function (obtained from uniport.org ) of the protein the phosphopeptide belongs to. Black and grey asterisks denote FDR<0.2 and p<0.01, respectively. Immunostaining of CAVN1 and <t>CAV1</t> when GMECs were treated with LGALS1 siRNA, IFNγ, or both. Green colour indicates CAV1, red colour indicates CAVN1. Red arrows denote co-staining of CAV1 and CAVN1 in the NT_V condition. LGALS1 , galectin-1 gene; GMEC, glomerular microvascular endothelial cells; IFNγ, interferon-γ; NT, non-targeting control; NT_V, non-targeting control and vehicle; PTM, post-translational modification.
Mouse Monoclonal Anti Cav1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse monoclonal anti cav1 antibody/product/Proteintech
Average 95 stars, based on 1 article reviews
mouse monoclonal anti cav1 antibody - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
mouse anti p caveolin 1  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology mouse anti p caveolin 1
A) Overview of treatment and phosphoproteome enrichment workflow. B) Phosphopeptides identified, quantified, and significant for each treatment and their interaction after correcting for matched unmodified peptides using MSStatsPTM in R. C) Volcano plots of phosphopeptide Log2FC of IFNγ treatment, LGALS1 siRNA, and both IFNγ and LGALS1 siRNA, compared to non-targeting control and vehicle plotted against –log10(p-value). Orange colour represents non-significant proteins, while blue colour represents those with p<0.01 (linear mixed-effects model), and green represents those with FDR: BH<0.2. D) Heatmap of 28 phosphopeptides significant in at least 1 comparison from panel C. Red colour indicates increased expression, blue colour indicates decreased expression, and black colour indicates phosphopeptides that were not found in that comparison. Colour on the top bar denotes function (obtained from uniport.org ) of the protein the phosphopeptide belongs to. Black and grey asterisks denote FDR<0.2 and p<0.01, respectively. Immunostaining of CAVN1 and <t>CAV1</t> when GMECs were treated with LGALS1 siRNA, IFNγ, or both. Green colour indicates CAV1, red colour indicates CAVN1. Red arrows denote co-staining of CAV1 and CAVN1 in the NT_V condition. LGALS1 , galectin-1 gene; GMEC, glomerular microvascular endothelial cells; IFNγ, interferon-γ; NT, non-targeting control; NT_V, non-targeting control and vehicle; PTM, post-translational modification.
Mouse Anti P Caveolin 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti p caveolin 1/product/Santa Cruz Biotechnology
Average 96 stars, based on 1 article reviews
mouse anti p caveolin 1 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
sc 53564 beta dystroglycan β dg mouse  (Santa Cruz Biotechnology)
97
Santa Cruz Biotechnology sc 53564 beta dystroglycan β dg mouse
A) Overview of treatment and phosphoproteome enrichment workflow. B) Phosphopeptides identified, quantified, and significant for each treatment and their interaction after correcting for matched unmodified peptides using MSStatsPTM in R. C) Volcano plots of phosphopeptide Log2FC of IFNγ treatment, LGALS1 siRNA, and both IFNγ and LGALS1 siRNA, compared to non-targeting control and vehicle plotted against –log10(p-value). Orange colour represents non-significant proteins, while blue colour represents those with p<0.01 (linear mixed-effects model), and green represents those with FDR: BH<0.2. D) Heatmap of 28 phosphopeptides significant in at least 1 comparison from panel C. Red colour indicates increased expression, blue colour indicates decreased expression, and black colour indicates phosphopeptides that were not found in that comparison. Colour on the top bar denotes function (obtained from uniport.org ) of the protein the phosphopeptide belongs to. Black and grey asterisks denote FDR<0.2 and p<0.01, respectively. Immunostaining of CAVN1 and <t>CAV1</t> when GMECs were treated with LGALS1 siRNA, IFNγ, or both. Green colour indicates CAV1, red colour indicates CAVN1. Red arrows denote co-staining of CAV1 and CAVN1 in the NT_V condition. LGALS1 , galectin-1 gene; GMEC, glomerular microvascular endothelial cells; IFNγ, interferon-γ; NT, non-targeting control; NT_V, non-targeting control and vehicle; PTM, post-translational modification.
Sc 53564 Beta Dystroglycan β Dg Mouse, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sc 53564 beta dystroglycan β dg mouse/product/Santa Cruz Biotechnology
Average 97 stars, based on 1 article reviews
sc 53564 beta dystroglycan β dg mouse - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier
mouse anti human caveolin 1  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology mouse anti human caveolin 1
A) Overview of treatment and phosphoproteome enrichment workflow. B) Phosphopeptides identified, quantified, and significant for each treatment and their interaction after correcting for matched unmodified peptides using MSStatsPTM in R. C) Volcano plots of phosphopeptide Log2FC of IFNγ treatment, LGALS1 siRNA, and both IFNγ and LGALS1 siRNA, compared to non-targeting control and vehicle plotted against –log10(p-value). Orange colour represents non-significant proteins, while blue colour represents those with p<0.01 (linear mixed-effects model), and green represents those with FDR: BH<0.2. D) Heatmap of 28 phosphopeptides significant in at least 1 comparison from panel C. Red colour indicates increased expression, blue colour indicates decreased expression, and black colour indicates phosphopeptides that were not found in that comparison. Colour on the top bar denotes function (obtained from uniport.org ) of the protein the phosphopeptide belongs to. Black and grey asterisks denote FDR<0.2 and p<0.01, respectively. Immunostaining of CAVN1 and <t>CAV1</t> when GMECs were treated with LGALS1 siRNA, IFNγ, or both. Green colour indicates CAV1, red colour indicates CAVN1. Red arrows denote co-staining of CAV1 and CAVN1 in the NT_V condition. LGALS1 , galectin-1 gene; GMEC, glomerular microvascular endothelial cells; IFNγ, interferon-γ; NT, non-targeting control; NT_V, non-targeting control and vehicle; PTM, post-translational modification.
Mouse Anti Human Caveolin 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti human caveolin 1/product/Santa Cruz Biotechnology
Average 96 stars, based on 1 article reviews
mouse anti human caveolin 1 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
caveolin 1 human mouse rat rabbit cell signaling  (Cell Signaling Technology Inc)
99
Cell Signaling Technology Inc caveolin 1 human mouse rat rabbit cell signaling
A) Overview of treatment and phosphoproteome enrichment workflow. B) Phosphopeptides identified, quantified, and significant for each treatment and their interaction after correcting for matched unmodified peptides using MSStatsPTM in R. C) Volcano plots of phosphopeptide Log2FC of IFNγ treatment, LGALS1 siRNA, and both IFNγ and LGALS1 siRNA, compared to non-targeting control and vehicle plotted against –log10(p-value). Orange colour represents non-significant proteins, while blue colour represents those with p<0.01 (linear mixed-effects model), and green represents those with FDR: BH<0.2. D) Heatmap of 28 phosphopeptides significant in at least 1 comparison from panel C. Red colour indicates increased expression, blue colour indicates decreased expression, and black colour indicates phosphopeptides that were not found in that comparison. Colour on the top bar denotes function (obtained from uniport.org ) of the protein the phosphopeptide belongs to. Black and grey asterisks denote FDR<0.2 and p<0.01, respectively. Immunostaining of CAVN1 and <t>CAV1</t> when GMECs were treated with LGALS1 siRNA, IFNγ, or both. Green colour indicates CAV1, red colour indicates CAVN1. Red arrows denote co-staining of CAV1 and CAVN1 in the NT_V condition. LGALS1 , galectin-1 gene; GMEC, glomerular microvascular endothelial cells; IFNγ, interferon-γ; NT, non-targeting control; NT_V, non-targeting control and vehicle; PTM, post-translational modification.
Caveolin 1 Human Mouse Rat Rabbit Cell Signaling, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/caveolin 1 human mouse rat rabbit cell signaling/product/Cell Signaling Technology Inc
Average 99 stars, based on 1 article reviews
caveolin 1 human mouse rat rabbit cell signaling - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier
mouse anti caveolin 1  (Santa Cruz Biotechnology)
97
Santa Cruz Biotechnology mouse anti caveolin 1
A) Overview of treatment and phosphoproteome enrichment workflow. B) Phosphopeptides identified, quantified, and significant for each treatment and their interaction after correcting for matched unmodified peptides using MSStatsPTM in R. C) Volcano plots of phosphopeptide Log2FC of IFNγ treatment, LGALS1 siRNA, and both IFNγ and LGALS1 siRNA, compared to non-targeting control and vehicle plotted against –log10(p-value). Orange colour represents non-significant proteins, while blue colour represents those with p<0.01 (linear mixed-effects model), and green represents those with FDR: BH<0.2. D) Heatmap of 28 phosphopeptides significant in at least 1 comparison from panel C. Red colour indicates increased expression, blue colour indicates decreased expression, and black colour indicates phosphopeptides that were not found in that comparison. Colour on the top bar denotes function (obtained from uniport.org ) of the protein the phosphopeptide belongs to. Black and grey asterisks denote FDR<0.2 and p<0.01, respectively. Immunostaining of CAVN1 and <t>CAV1</t> when GMECs were treated with LGALS1 siRNA, IFNγ, or both. Green colour indicates CAV1, red colour indicates CAVN1. Red arrows denote co-staining of CAV1 and CAVN1 in the NT_V condition. LGALS1 , galectin-1 gene; GMEC, glomerular microvascular endothelial cells; IFNγ, interferon-γ; NT, non-targeting control; NT_V, non-targeting control and vehicle; PTM, post-translational modification.
Mouse Anti Caveolin 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti caveolin 1/product/Santa Cruz Biotechnology
Average 97 stars, based on 1 article reviews
mouse anti caveolin 1 - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier
caveolin-1 anti-human mouse  (Santa Cruz Biotechnology)
90
Santa Cruz Biotechnology caveolin-1 anti-human mouse
A) Overview of treatment and phosphoproteome enrichment workflow. B) Phosphopeptides identified, quantified, and significant for each treatment and their interaction after correcting for matched unmodified peptides using MSStatsPTM in R. C) Volcano plots of phosphopeptide Log2FC of IFNγ treatment, LGALS1 siRNA, and both IFNγ and LGALS1 siRNA, compared to non-targeting control and vehicle plotted against –log10(p-value). Orange colour represents non-significant proteins, while blue colour represents those with p<0.01 (linear mixed-effects model), and green represents those with FDR: BH<0.2. D) Heatmap of 28 phosphopeptides significant in at least 1 comparison from panel C. Red colour indicates increased expression, blue colour indicates decreased expression, and black colour indicates phosphopeptides that were not found in that comparison. Colour on the top bar denotes function (obtained from uniport.org ) of the protein the phosphopeptide belongs to. Black and grey asterisks denote FDR<0.2 and p<0.01, respectively. Immunostaining of CAVN1 and <t>CAV1</t> when GMECs were treated with LGALS1 siRNA, IFNγ, or both. Green colour indicates CAV1, red colour indicates CAVN1. Red arrows denote co-staining of CAV1 and CAVN1 in the NT_V condition. LGALS1 , galectin-1 gene; GMEC, glomerular microvascular endothelial cells; IFNγ, interferon-γ; NT, non-targeting control; NT_V, non-targeting control and vehicle; PTM, post-translational modification.
Caveolin 1 Anti Human Mouse, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/caveolin-1 anti-human mouse/product/Santa Cruz Biotechnology
Average 90 stars, based on 1 article reviews
caveolin-1 anti-human mouse - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
mouse anti-human caveolin-1 (cav1)  (Thermo Fisher)
90
Thermo Fisher mouse anti-human caveolin-1 (cav1)
A) Overview of treatment and phosphoproteome enrichment workflow. B) Phosphopeptides identified, quantified, and significant for each treatment and their interaction after correcting for matched unmodified peptides using MSStatsPTM in R. C) Volcano plots of phosphopeptide Log2FC of IFNγ treatment, LGALS1 siRNA, and both IFNγ and LGALS1 siRNA, compared to non-targeting control and vehicle plotted against –log10(p-value). Orange colour represents non-significant proteins, while blue colour represents those with p<0.01 (linear mixed-effects model), and green represents those with FDR: BH<0.2. D) Heatmap of 28 phosphopeptides significant in at least 1 comparison from panel C. Red colour indicates increased expression, blue colour indicates decreased expression, and black colour indicates phosphopeptides that were not found in that comparison. Colour on the top bar denotes function (obtained from uniport.org ) of the protein the phosphopeptide belongs to. Black and grey asterisks denote FDR<0.2 and p<0.01, respectively. Immunostaining of CAVN1 and <t>CAV1</t> when GMECs were treated with LGALS1 siRNA, IFNγ, or both. Green colour indicates CAV1, red colour indicates CAVN1. Red arrows denote co-staining of CAV1 and CAVN1 in the NT_V condition. LGALS1 , galectin-1 gene; GMEC, glomerular microvascular endothelial cells; IFNγ, interferon-γ; NT, non-targeting control; NT_V, non-targeting control and vehicle; PTM, post-translational modification.
Mouse Anti Human Caveolin 1 (Cav1), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti-human caveolin-1 (cav1)/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
mouse anti-human caveolin-1 (cav1) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


A) Overview of treatment and phosphoproteome enrichment workflow. B) Phosphopeptides identified, quantified, and significant for each treatment and their interaction after correcting for matched unmodified peptides using MSStatsPTM in R. C) Volcano plots of phosphopeptide Log2FC of IFNγ treatment, LGALS1 siRNA, and both IFNγ and LGALS1 siRNA, compared to non-targeting control and vehicle plotted against –log10(p-value). Orange colour represents non-significant proteins, while blue colour represents those with p<0.01 (linear mixed-effects model), and green represents those with FDR: BH<0.2. D) Heatmap of 28 phosphopeptides significant in at least 1 comparison from panel C. Red colour indicates increased expression, blue colour indicates decreased expression, and black colour indicates phosphopeptides that were not found in that comparison. Colour on the top bar denotes function (obtained from uniport.org ) of the protein the phosphopeptide belongs to. Black and grey asterisks denote FDR<0.2 and p<0.01, respectively. Immunostaining of CAVN1 and CAV1 when GMECs were treated with LGALS1 siRNA, IFNγ, or both. Green colour indicates CAV1, red colour indicates CAVN1. Red arrows denote co-staining of CAV1 and CAVN1 in the NT_V condition. LGALS1 , galectin-1 gene; GMEC, glomerular microvascular endothelial cells; IFNγ, interferon-γ; NT, non-targeting control; NT_V, non-targeting control and vehicle; PTM, post-translational modification.

Journal: bioRxiv

Article Title: Galectin-1 Modulates Cell Adhesions, Caveolae, and Vascular Permeability in Kidney Endothelial Cells – Insights from Proteomics, Phosphoproteomics, and Functional Studies

doi: 10.64898/2026.03.03.709385

Figure Lengend Snippet: A) Overview of treatment and phosphoproteome enrichment workflow. B) Phosphopeptides identified, quantified, and significant for each treatment and their interaction after correcting for matched unmodified peptides using MSStatsPTM in R. C) Volcano plots of phosphopeptide Log2FC of IFNγ treatment, LGALS1 siRNA, and both IFNγ and LGALS1 siRNA, compared to non-targeting control and vehicle plotted against –log10(p-value). Orange colour represents non-significant proteins, while blue colour represents those with p<0.01 (linear mixed-effects model), and green represents those with FDR: BH<0.2. D) Heatmap of 28 phosphopeptides significant in at least 1 comparison from panel C. Red colour indicates increased expression, blue colour indicates decreased expression, and black colour indicates phosphopeptides that were not found in that comparison. Colour on the top bar denotes function (obtained from uniport.org ) of the protein the phosphopeptide belongs to. Black and grey asterisks denote FDR<0.2 and p<0.01, respectively. Immunostaining of CAVN1 and CAV1 when GMECs were treated with LGALS1 siRNA, IFNγ, or both. Green colour indicates CAV1, red colour indicates CAVN1. Red arrows denote co-staining of CAV1 and CAVN1 in the NT_V condition. LGALS1 , galectin-1 gene; GMEC, glomerular microvascular endothelial cells; IFNγ, interferon-γ; NT, non-targeting control; NT_V, non-targeting control and vehicle; PTM, post-translational modification.

Article Snippet: Samples were incubated overnight at 4°C with rabbit polyclonal anti-galectin-1 antibody (1:100; GTX101566; GeneTex), rabbit polyclonal anti-CAVN1 antibody (1:1000; 18892-1-AP; Proteintech), or mouse monoclonal anti-CAV1 antibody (1:1000; 66067-1-IG; Proteintech).

Techniques: Phospho-proteomics, Control, Comparison, Expressing, Immunostaining, Staining, Modification